IMR Press / JIN / Volume 21 / Issue 5 / DOI: 10.31083/j.jin2105141
Open Access Review
Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions
Show Less
1 GCA-Centro Spoke AO Cannizzaro, Catania, IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy
2 Stroke Unit, AOU Policlinico Universitario, 98125 Messina, Italy
3 Neurorehabilitation Unit, IRCCS Centro Neurolesi “Bonino Pulejo”, 98124 Messina, Italy
*Correspondence: (Rocco Salvatore Calabrò)
Academic Editor: Parisa Gazerani
J. Integr. Neurosci. 2022, 21(5), 141;
Submitted: 9 May 2022 | Revised: 19 June 2022 | Accepted: 21 June 2022 | Published: 10 August 2022
(This article belongs to the Special Issue Migraine: from Bench to Clinical Practice)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Chronic migraine belongs to the “chronic long-duration headaches”, and it is associated to high burden and significant economic impact. Treatment for both episodic (EM) and chronic migraine (CM) is based on the management of acute attacks and their prevention. For moderate/severe attacks, pharmacological therapies are triptans, dihydroergotamine nasal sprays or injections or neuroleptics, non-steroidal anti-inflammatory drugs, and corticosteroids. Chronic migraine belongs to the “chronic long-duration headaches”, and it is associated to high burden and significant economic impact. Treatment for both episodic (EM) and chronic migraine (CM) is based on the management of acute attacks and their prevention. For moderate/severe attacks, pharmacological therapies are triptans, dihydroergotamine nasal sprays or injections or neuroleptics, non-steroidal anti-inflammatory drugs, and corticosteroids. The pathophysiology of CM is characterized by an abnormal activation of the trigemino-vascular system in the meninges causing a neurogenic inflammation, which explains the use of anti-inflammatory during attacks. It seems that the objective of the preventive therapy with the botulin toxin OnaBoNT-A consists in interrupting the release of CGRP and other neuropeptides as well as the activation of C-fiber nociceptor and of the nearby A-delta fibers. The protocol for migraine treatment with OnaBoNT-A injections consists of 31–39 pericranial injection sites involving seven muscle groups bilaterally in specific areas of the head and neck, with a total dose of between 155 and 195 units, every three months. The severe adverse events reported with high doses of botulin toxin for spasticity, have not been reported for CM treated with OnabotA at the labeled dose. The established improvement with onabotulinumtoxinA treatment in CM patients had a positive impact not only in reduction monthly headache days but also in improving quality of life, with reduction in both healthcare resource utilisation (HRU) and work impairment. Aim of this review was to give an overview on the use of BoNT-A in patients with CM, giving practical advices on the clinical indications.

chronic migraine
onabotulinum toxin A
botulin toxin
calcitonin gene-related peptide (CGRP) pathway
1. Introduction

Migraine is one of most disabling chronic pathology [1] with a negative impact on patients’ quality of life. The disease affects approximately 2% of the general population [2], and the prevalence is about 7% in men and around 24% in women. Moreover, it also affects about 4% of children [3, 4]. The World Health Organization Global Burden of Disease Study 2010 showed that migraine was the fourth most disabling medical disorder among women [5], and the seventh most disabling medical disorder overall worldwide.

Migraine can be classified as with or without aura (characterized by visual, sensory or language symptoms) and as chronic or episodic based on the duration of symptoms. Chronic migraine (CM) is defined by the International Headache Society (IHS) as “headache on at least 15 days a month, for more than 3 months, and 8 of these headache days must be migraine headaches, or relieved by a triptan or ergot derivative and no medication overuse (Fig. 1) [6].

Fig. 1.

ICHD-3 Diagnostic Criteria for CM. *Legend: CM, chronic migraine; ICHD-3, International Classification of Headache Disorders (third revision).

Chronic migraine, belongs to the “chronic long-duration headaches” and it is associated to high burden and significant economic impact [7]. It has been reported that CM patients lost at least 5 days of household work over a 3-month period compared with 24% of those with EM [7]. Treatment for both episodic and chronic migraine is based on the management of acute attacks and their prevention. Mild and sporadic migraine attacks can be managed with non-pharmacologic interventions, such as laying down in dark room, cold compresses or pressure on the painful areas, and avoiding migraine triggers. For moderate/severe attacks, pharmacological therapy is needed. Triptans should be taken early during the attack, with pain reduction usually within 2 hours, and should not be used more than two days per week in order to decrease the risk of rebound headaches. Other drugs commonly taken are the dihydroergotamine nasal sprays or injections or neuroleptics, non-steroidal anti-inflammatory drugs and corticosteroids. However, the treatments usually are slight efficient and limited by side-effects, as unintentional abuse [8]. On the other hand, although more than 40 drug therapies are used to prevent migraine, by now, only five agents are approved by the US Food and Drug Administration (FDA) for the prevention of EM: the beta-adrenergic blocking agents, propranolol and timolol, and the anticonvulsants divalproex sodium or sodium valproate and topiramate [9].

Furthermore, the only therapies approved for the prevention of CM are the onabotulinum toxin A (BoNT-A) [10], and the monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway [11].

Aim of this paper was to give an overview of the treatment with BoNT-A for CM, giving useful clinical indications. This may offer a guide on the use of botulinum toxin for the preventive treatment of migraine, including the sites and dose of injection, the approved indications for usage, the reported adverse events and impact on social problem.

2. Pathophysiology of Migraine and Rationale for the Use of Botulin Toxin

Significant progress has been made in the understanding of migraine pathophysiology, which is fundamental for the implementation of treatment options. Migraine is considered a primary central nervous system disorder involving several pathways, including the meningeal blood vessel [1] flow and the activation of some cortical and subcortical structures [12]. The pathophysiology of migraine is still debated [12]. The beginning of a migraine attack might be related to the activation of C-fiber nociceptors in the dura by the diffusion to the meninges of the neuropeptide calcitonin gene–related peptide (CGRP) and neurotrasmitters from the cerebral cortex during the spreading depression [13, 14]. The C-fiber nociceptors and A-delta pain fibers [15] and, subsequently, the second order sensory neurons of the trigeminocervical complex in the brainstem are activated [11]. Triggers are exogenous factors (as peripheral stress, dietary products, environmental changes) [12], that activate sensory afferents, as well as endogenous factors (spreading depression, hormonal fluctuation, demodulated brain networks) (Fig. 2, Ref. [12, 16, 17, 18, 19]) [20].

Fig. 2.

The pathophysiological mechanisms involved in migraine attacks, with the pivotal role of the trigeminovascular system. CDS, cortical depression spreading.

Therefore, the pathophysiology is characterized by abnormal activation of the trigemino-vascular system in the meninges causing a neurogenic inflammation, that explains the use of anti-inflammatory during attacks [16]. The neuroinflammation lead to a double response: (i) a peripheral sensitization, mediated by an excessive response of primary afferent nociceptive neurons to external exogenous stressful [21], expressed phenotypically by throbbing pain, exacerbated by bending over or coughing [17]. The nociceptors and inflammatory mediators involved are bradykinin, histamine, serotonin, prostaglandin E2 and interleukins 1, 6 and 8 and tumour necrosis factor-alpha [16, 22], and (ii) a central sensitization which is caused by hyperexcitability of nociceptive neurons in the dorsal horn of the spinal cord [16]. This process is mediated by the CGRP, which has a pivotal role in [11] the nociceptive transmission and migraine chronification.

It seems that the objective of the preventive therapy with OnaBoNT-A consists in interrupting the release of CGRP and other neuropeptides as well as the activation of C-fiber nociceptor and of the nearby A-delta fibers [15].

3. Mechanism of Action of OnaBoNT-A

OnaBoNT-A consists of two polypeptide chains joined by a disulfide bond. There are seven serotypes of botulin toxin: from A to G. However, the form that has been approved for the treatment of migraine is the onabotulinum toxin A, OnaBoNT-A [9, 23]. Moreover, the toxin has been utilised to treat craniocervical dystonia, spasticity, detrusor instability, hyperhidrosis and hypersalivation. The oral ingestion of OnaBoNT-A causes intoxication and produces acute and life-threatening muscle paralysis known as botulism [24]. Indeed, the BoNTs prevents the pre-synaptic release of the neurotransmitter acetylcholine at the synaptic level of neuromuscular junction causing dose-dependent, reversible flaccid paralysis [25, 26]. At the pre-synaptic space there are vesicles, nearby the terminal nerve [27], creating a pool filled by neurotransmitters, whose contents could be released in the synaptic junction to activate a signal transmission process after exocytosis. This last process is realized only after assemblation of syntaxin 1A and SNAP-25 (synaptosomal-associated protein), on the plasma membrane and synaptobrevin 2 (VAMP2) on the vesicular membrane to bridge the two opposite membranes in the ‘fusion’ step [20, 28]. The fusion complex VAMP/synaptobrevin/SNAP-25 and syntaxin, is called SNARE complex [29]. When OnaBoNT-A is injected, it is endocytosed and enters in the cell cytoplasm cleaving the C-terminus of SNAP-25, target of botulinum neurotoxins types A (BoNT-A) and BoNT-E proteolytic mechanism both in motor nerve terminals and in sensory nerve terminals [30]. As a result, the peripheral release of neuropeptides and inflammatory peptides [25] is blocked as well as the release of CGRP [28], distributed in the peripheral and central nervous system (CNS) [31] playing a therapeutic role in migraine [32].

CGRP is released in the meninges and in the nucleus trigeminalis caudalis. It is potentiated by the P2Y purinergic receptors in satellite glia cells [33], leading to cytokine release under the influence of sexual hormones, such as the 17-beta-estradiol. On the other hand, it is attenuated by the P2X3 receptor-mediated peripheral pain signal transduction in neuronal afferents [34]. The reduction in nociceptive activity in extracranial nerves or through reduction in blood CGRP levels in patients with chronic migraine has been showed by decrease in headache frequency [35].

Moreover, certain receptors, such as the transient receptor potential cation channel subfamily V member 1, TRPV1 [36], play an important role in pain transmission and sensitization, and could be targeted by other drugs.

4. Toward a Validation of the Use of Botulin Toxin in Migraine

The first case of botulism has been published in 1820, and the pathogen agent was successively isolated in 1897 and named as bacillus botulinum and then as clostridium botulinum [37]. Taking into consideration its potential in the medical field, botulin toxin has been used in 1977 for the treatment of strabism, and in the 1989 was also approved for blepharospasm and hemifacial spasm [37]. Only in the nineties, OnaBoNT-A has been used for tension-type headache, and, since then, several case reports with positive effect of chronic migraine were reported [9, 10, 11]. The first clinical trial was described in 2000 by Allergan, that obtained the rights to Oculinum [38]. Even though the trial showed contrasting results with benefit only with low doses (25 UI) instead of higher doses (75 UI), an increasing interest on clinical trials has amplified the number of clinical trials on OnaBoNT-A in migraine. At first the OnaBoNT-A was approved only for preventive treatment of chronic migraine. Later two larger sample OnaBoNT-A vs placebo RDBPC trials of patients with chronic headache were carried out and showed the efficacy of OnaBoNT-A on reducing headache days per month more than 50% (32.7 vs. 15.0%, p = 0.027) [39]. Nevertheless, a later episodic migraine trial in 2007 showed no differences between OnaBoNT-A and placebo [25]. However, a post-hoc analysis showed positive results in patients with a headache frequency more than 12 days per month [23].

The next important trial was the phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) involving 1384 patients [10]. Although the primary endpoint of reduction in mean change in headache episodes from baseline failed, a significant reduction in headache day per month as secondary endpoint has been shown. However, the study demonstrated a slight difference in reduction of headache days compared with placebo (2.3 days) and global pain intensity in patients with CM. On the other hand, no significant findings for botulinum toxin injection in the of tension type and episodic migraine were found [40, 41, 42]. The efficacy of OnaBoNT-A in CM was particularly shown in the two randomised placebo-controlled phase 3 clinical trials, PREEMPT I and II [10, 23]. Both studies showed a decrease in headache days and migraine days with OnaBoNT-A as compared to placebo [10, 23]. A pooled analysis of the two previous studies showed a decrease from baseline in frequency of headache days by 2 days per month at week 24 and at all other time points and a statistically significant improvement (p < 0.001) in the Headache Impact Test (HIT)-6 [43].

Moreover, in the large long-term open-label COMPEL (Chronic Migraine Onabotulinum toxin-A Prolonged Efficacy Open Label) study, Blumenfeld et al. [44] showed no differences in the number of moderate or severe headache days per month between patients with and without daily headache. However, a significant reduction in frequency of headache days at weeks 24, 60 and 108 was shown. The HIT-6 scores were significantly reduced at each time point in both groups from baseline (65.6 and 64.6, respectively) to 60 or less. For these reasons, OnaBoNT-A was approved only for CM [44].

A recent metanalysis showed that OnaBoNT-A, topiramate, and acupuncture reduce headache days and migraine days a week 12 with no significant difference between the three treatments in most of the outcomes investigated; however, topiramate caused higher adverse events and number of dropout. The authors concluded that, even though all of the three treatments were effective in the prophylactic treatment of CM, OnaBoNT-A should be considered as the first-choice respect to topiramate, because of the better effect in reducing headache days and migraine days a week 16 and the lower acceptability of topiramate, and the acupuncture, because of the several sessions needed (at least 10 sessions, one per week) [45] with important economic costs [46].

Moreover, a systematic metanalysis on the treatment of CM with OnaBoNT-A demonstrated its effectiveness compared to placebo, as well as the non-inferiority to the comparators valproic acid, topiramate and histamine, with a better safety and tolerability profile than oral prophylactics [47].

5. Protocol of the Use of Botulin Toxin in Migraine

Suitable patients for treatment with BoNT-A toxin are (i) subjects over 18 years old; (ii) 15 days per month with headache lasting 4 hours per day or with >3 days per month of headache-related disability; (iii) patients with adverse events or contraindications to triptans or other vasoactive medications; and (iv) severe or prolonged attacks [48]. Others factors to choose botulin toxin as a preventive therapy are: the frequency of headaches with the level of burden; overuse; poor response to acute therapy; and comorbidities such as depression).

Because of the origin of migraine pain come from the meninges and the forehead, bridge of the nose, the temples, the back of the head, and neck, injections of peripheral scalp results in retrograde transportation through the connections (skull sutures) to the meninges, Gasserian trigeminal ganglion and occipital nerves through dorsal roots to the cervical spine [49, 50, 51].

Therefore, the protocol for migraine treatment with OnaBoNT-A injections involving of 31–39 pericranial injection sites consisting of seven muscle groups bilaterally in specific areas of the head and neck (Fig. 3) [10, 23] with a total dose of between 155 and 195 units [44], every three months. About the muscle groups, in the temporal region the injection should be done >45 mm above the zygomatic arch to avoid the tendon [52, 53]. The greater occipital nerve is a sensory nerve derived primarily from the C2 dorsal root and its block is used to treat occipital headaches [54].

Fig. 3.

The main injection sites for botulin toxin in the prevention of chronic migraine.

Recently, an algorithm of OnaBoNT-A in migraine has been proposed based on the clinical response, evaluated by headache diaries or validated tools as: rating scale to rate the intensity of headache [55], MIDAS or HIT-6 score for disability [56, 57], MSQ for QoL [58], PGCI for patient’s impression of efficacy [59]. Four categories have been classified: excellent responders, when the patients experienced a reduction in headache days 75% or the same percentage of improvement on the above tools. All patients started with a dose of 155, according to the American Headache guidelines [60], that could be increased to 195 UI and injected every three months for a year. If the efficacy persists after 1 year, the injections should be performed every 4 months, and discontinuation should be considered after 2 years with the same response [55].

The second group are called good responders for a reduction of headache days or scores from 50% to <75%. The authors suggested to start with a dose of 155 UI and, based on the response, it should be considered to adjunct a second treatment with CGRP-targeting if a number 8 headache day monthly persists. After two years, the treatment could be injected every 4 months.

When a response from 30% to <50% is recorded, the patients should be categorized as low responders. The started dose is 155 UI, and if they continue to be low responders two options are possible: (1) to continue with OnaBoNT-A plus oral preventative therapy for at least 1 year. Based on the response, in the second year, we have to consider to drop off the oral therapy and to continue ONABONT-Aevery 3–4 months; (2) to switch to an approved CGRP-targeting monoclonal antibodies (mAbs) when low response is persisting after 2 cycles of OnaBoNT-A and oral therapy.

Lastly, patients who respond with a reduction of headache days <30% are called non-responders. At the second injection, an oral therapy should be added as well as an increase of OnaBoNT-A dose. If no responses are noted after 2 cycles, a switch to CGRP-targeting mAb should be considered (see Table 1, Ref. [55]).

Table 1.Treatment algorithm for chronic migraine [55].
Responders Headache days 1 dose 1 year treatment 2 year 3 year
Excellent reduction 75% started with a dose of 155 Every 3 months (dose 155–195UI) Continue monotherapy Continue monotherapy Every 4 months Discontinuation
Good reduction from 50% to <75% started with a dose of 155 Every 3 months (dose 195UI) At 6 months consider OnaBont-A+ oral therapy Continue politherapy Every 4 months Increase interval
Low reduction from 30% to <50% started with a dose of 155 Every 3 months (dose 195UI) At 3 months consider ONABONT-A+ oral therapy At 9 months consider to switch to mAB Every 3 months OnaBOnt-A monotherapy every 3 months
Non- responders reduction from <30% started with a dose of 155 Every 3 months (dose 195UI) At 3 months ONABONT-A+ oral therapy At 6–9 months consider to switch to mAB / /

About the dosage of OnaBont-A+, a recent prospective study compared the efficacy of 195 U in 172 patients to 155 patients treated with 155 U of OnaBont-A+. The authors showed a higher efficacy of 195 U in reducing the mean headache days every three months of evaluation period (p < 0.001) with a significantly higher reduction of migraine days (p < 0.001) as well as significantly improvement of the overuse of acute pain medications (p < 0.001) and as a reduction in the mean of HIT-6 score (p < 0.05), filled every six months [61].

The long-lasting efficacy of OnaBoNt-A+ has been shown in a long-term study of 2015 on 132 patients with CM [62]. The study showed that botulinum toxin is effective after one year of treatment with injection every three months, with only 9.3% of patients dropped after one year for lost of efficacy, likely due to worsening of migraine or a development of antibodies. Meanwhile, no failure after three years of treatment were obtained. The treatment should not be delayed after three-four months and should not be stopped unless worsening of migraine frequency and pain. As adverse events, the frontal and temporal atrophy muscles was reported in two patients without pain. However, injections were continued every four months [62].

In a small study with 90 patients with CM, it has been shown that patients injected during the afternoon showed a lower average of total number of headache days during 3 months following injection than the morning-treated patients (p = 0.0007) [63].

6. New Treatment Options

OnabotulinumtoxinA is the only agent specifically approved for the prevention of CM in 2012 [64].

Recently four monoclonal anti-CGRP antibodies (mAbs-CGRP) have been developed as a new therapeutic for CM: one against the CGRP-R (erenumab) and three against the CGRP peptide or ligand (eptinezumab, fremanezumab and galcanezumab). Although, OnaBont-A and mAbs-CGRP showed a good efficacy, safety profile and tolerability studies on comparison efficacy are missing. CGRP/CGRP-R mAbs are recommended for the treatment of episodic migraine (>4 pain days per month) as well as CM [64] reducing the number of migraine days per month compared to placebo (50% reduction, 4.7 days), and a significant reduction in the drop out, especially with the 140 mg [47]. Fremanezumab is administered at the doses of 225 mg monthly and 675 mg quarterly and showed a significant decrease in the mean number of migraine days (3.2 and 3.8 days) and a decrease in the number of headache days of 2.1 and 1.8 days [65, 66]. Eptinezumab is administered intravenously at the doses of 100 mg and 300 mg every quarter and showed a statistically significant difference in the reduction in the number of migraine days, 2.0 and 2.6 days respectively [67].

Galcanezumab is injected at the doses of 120 mg or 240 mg per month with a significant decrease in the average number of migraine days, 2.1 and 1.9 days compared to the placebo group [68].

Non-invasive neuromodulation could be of help in some cases where toxins and other pharmacological treatments fail.

The data from literature indicates that Transcranial magnetic stimulation, TMS, can consistently reduce the number of migraine days per month, mitigate the intensity and duration of migraine attacks for several days after TMS application, up to one month, interrupt migraine attack quickly, and improve the quality of life. In addition, TMS is safe and well-tolerated, also considering that the majority of trials employed subthreshold stimulation intensities. Unfortunately, the non-invasive TMS devices are relatively expensive, even if the method seems to be cost-effective in some specific cases: it is cheaper than botulinum toxin-A for chronic migraine treatment, as well as cheaper than the whole, complex pharmacological management of chronic migraine) [69, 70].

Besides, transcranial direct current stimulation (tDCS) is a promising effective, preventive, and safe method for migraine treatment. Indeed, a recent systematic review has shown that tDCS applied on the primary motor cortex (M1), as well as on visual cortex VC could reduce the number of migraine days per month in patients with migraine [71].

Finally, combined approaches may lead to some additional benefit in CM [18, 19, 72, 73], and should be considered the future on chronic intractable migraine. Combination of CGRP mAbs and onaBoNtA treatment in CM patients has been recently studied in 257 patients with an effective additive or synergistic result and well tolerated effect. However, CGRP mAb were discontinued more frequently than onabotulinumtoxinA (23.3 vs. 3.3%), usually for lack of insurance reimbursement (42%) or a lack of effect (21%) [74].

A recent study has shown, for the first time ever, the therapeutic effect of mindfulness practices associated with left dorsolateral prefrontal cortex anodal tDCS in improving the level of full attention and analgesic benefits in this patient population [75, 76].

7. Botulin Toxin Adverse Events

The long-term real-world PREEMPT trials showed that about 40–73% of patients reported one or more adverse event with OnaBoNt-A [44, 77] consisting in neck pain (4%), musculoskeletal pain (2%), migraine or worsening of migraine (1–8.7%) and blurred vision (1%) [78, 79]. However, in patients continuing the injections, the incidence rate reduced in subsequent treatment session, showing a satisfied effect over the slight adverse events [80, 81].

The severe adverse events reported with high doses of botulin toxin for spasticity, have not been reported for CM treated with onabotA at the labeled dose [82]. The safety was shown even in infants breast-fed by lactating women treated for CM [83]. About safety in pregnancy women, adverse events were similar to the general population [84].

8. Impact of Botulinum Toxin Treatment in Migraine on Social Burden

The established improvement with onaboNTA treatment in CM patients had a positive impact not only in reduction monthly headache days but also in improving quality of life, with reduction in both healthcare resource utilisation (HRU) and work impairment [85, 86]. Compared with episodic migraine, patients with CM showed diminished quality of life [87], a higher level of disability [88, 89], higher healthcare utilisation and reduced productivity, developing in a higher economic burden [87]. CM also negatively influenced the overall health as well as marital, childcare, relationships, career/financial achievement and stability [90]. Moreover, CM is associated with substantial disability, healthcare resource utilisation (HRU), and economic burden [88, 89, 90, 91, 92, 93, 94].

Notably, data from the PREEMPT clinical trials, the evaluation of quality of life in the REPOSE study, and resource utilization estimates the International Burden of Migraine Study (IBMS) have revealed the cost-effective resource of the onaboNTA in UK [95].

The multi-center REPOSE study showed a statistically significant reduction in headache-related hospitalizations and healthcare professional visits before baseline; reduction from 41.7% at baseline to 13.5% at visit 8 of family doctor visits as well as a reduction from 61.7% to 5.2% of visits to a medical specialist, at the end of the 2-year observation period. Moreover, there was a reduction in percentage of 77% and 78% of patients absent from school or work as well as an increased performance at school or work over the 2-year period. Therefore, no patients reported headache-related disability at visit 8 [96].

In addition, the COMPEL study showed the efficacy of onabotulinumtoxinA treatment also in headache-related HCP visits, emergency room and urgent care visits, and diagnostic tests in adults with CM [44].

Another real-world, open-label study of CM patients showed a reduction of emergency department visits (55%), urgent care visits (59%) and hospitalizations (57%) as compared to the 6 months before initiating botulinum toxin treatment [97].

9. Conclusions

Chronic migraine impacts the quality of life of the patients and, therefore, to reduce the frequency and duration of headache attacks should be the first object of the treatment. To this end, Botulin toxin has been shown as a valuable treatment for the prevention of CM. In low or non-responder patients a combination therapy with oral drugs or monoclonal antibodies (Erenumab, fremanezumab, and galcanezumab) should be considered, even though few studies are available [7]. However, the management of CM remains difficult because of the necessity of a better understanding of the pathophysiology of CM and the effect of different combination of CM therapy, as well as the discovery of others therapeutic targets.

Author Contributions

RSC designed the manuscript structure. LR, and GR discussed and wrote the content and exchanged ideas and suggestions throughout the writing process. DM and CC exchanged ideas and suggestions throughout the writing process. RSC edited and critically revised the paper and gave the final approval for the version to be published. All authors have read and agreed to the published version of the manuscript.

Ethics Approval and Consent to Participate

Not applicable.


Thanks to all the peer reviewers for their opinions and suggestions.


This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest. RSC is serving as one of the Editorial Board members/Guest editors of this journal. We declare that RSC had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Dr. Parisa Gazerani.

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

World Health Organization. World Health Report. 2001. Available at: (Accessed: 23 April 2022).
Dodick DW. Migraine. The Lancet. 2018; 391: 1315–1330.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine — Current Understanding and Treatment. New England Journal of Medicine. 2002; 346: 257–270.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343–349.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2163–2196.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.
Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71: 559–566.
Argyriou AA, Vikelis M, Mantovani E, Litsardopoulos P, Tamburin S. Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion. Expert Review of Neurotherapeutics. 2021; 21: 235–248.
Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021; 397: 1505–1518.
Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793–803.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nature Reviews Neurology. 2018; 14: 338–350.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: a Disorder of Sensory Processing. Physiological Reviews. 2017; 97: 553–622.
Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Annals of Neurology. 2011; 69: 855–865.
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine. 2002; 8: 136–142.
Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual Therapy with Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: is there a Rationale? Headach. 2020; 60: 1056–1065.
Ramachandran R. Neurogenic inflammation and its role in migraine. Seminars in Immunopathology. 2018; 40: 301–314.
Burstein R, Noseda R, Borsook D. Migraine: Multiple Processes, Complex Pathophysiology. Journal of Neuroscience. 2015; 35: 6619–6629.
Tassorelli C, Aguggia M, De Tommaso M, Geppetti P, Grazzi L, Pini LA, et al. Onabotulinumtoxin a for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. The Journal of Headache and Pain. 2017; 18: 66.
American Academy of Neurology. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. 2018. Available at: (Accessed: 21 March 2022).
Martinelli D, Arceri S, Tronconi L, Tassorelli C. Chronic migraine and Botulinum Toxin Type a: where do paths cross? Toxicon. 2020; 178: 69–76.
Burstein R, Jakubowski M, Rauch SD. The science of migraine. Journal of Vestibular Research. 2011; 21: 305–314.
Sachs D, Cunha FQ, Poole S, Ferreira SH. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain. 2002; 96: 89–97.
Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804–814.
Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. The Indian Journal of Medical Research. 2010; 132: 489–503
Restani L, Novelli E, Bottari D, Leone P, Barone I, Galli-Resta L, et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic. 2012; 13: 1083–1089.
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature Reviews Microbiology. 2014; 12: 535–549.
Verhage M, Sørensen JB. Vesicle Docking in Regulated Exocytosis. Traffic. 2008; 9: 1414–1424.
Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: a Narrative Review. Headache. 2020; 60: 1259–1272.
Hong W, Lev S. Tethering the assembly of SNARE complexes. Trends in Cell Biology. 2014; 24: 35–43.
Lu B. The destructive effect of botulinum neurotoxins on the SNARE protein: SNAP-25 and synaptic membrane fusion. PeerJ. 2015; 3: e1065.
Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology. 2010; 6: 573–582.
Ramachandran R, Lam C, Yaksh TL. Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents. Neurobiology of Disease. 2015; 79: 111–122.
Ceruti S, Villa G, Fumagalli M, Colombo L, Magni G, Zanardelli M, et al. Calcitonin Gene-Related Peptide-Mediated Enhancement of Purinergic Neuron/Glia Communication by the Algogenic Factor Bradykinin in Mouse Trigeminal Ganglia from Wild-Type and R192Q Cav2.1 Knock-in Mice: Implications for Basic Mechanisms of Migraine Pain. Journal of Neuroscience. 2011; 31: 3638–3649.
Lu Y, Jiang Q, Yu L, Lu Z, Meng S, Su D, et al. 17β-Estradiol Rapidly Attenuates P2X3 Receptor-Mediated Peripheral Pain Signal Transduction via ERα and GPR30. Endocrinology. 2013; 154: 2421–2433.
Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015; 156: 820–824.
Zhang X, Strassman AM, Novack V, Brin MF, Burstein R. Extracranial injections of botulinum neurotoxin type a inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia. 2016; 36: 875–886.
Jabbari B. History of Botulinum Toxin Treatment in Movement Disorders. Tremor and Other Hyperkinetic Movements. 2016; 6: 394.
Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type a (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngology–Head and Neck Surgery. 2000; 123: 669–676.
Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache. 2005; 45: 293–307.
Elkind AH, O’Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. A Series of Three Sequential, Randomized, Controlled Studies of Repeated Treatments with Botulinum Toxin Type a for Migraine Prophylaxis. The Journal of Pain. 2006; 7: 688–696.
Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt I, Frese A. Botulinum Toxin a in the Prophylactic Treatment of Migraine – a Randomized, Double-Blind, Placebo-Controlled Study. Cephalalgia. 2004; 24: 838–843.
Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum Toxin Type a as a Migraine Preventive Treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40: 445–450.
Atraszkiewicz D, Ito R, Bahra A. The efficacy of botulinum toxin type-a for intractable chronic migraine patients with no pain-free time. British Journal of Pain. 2022; 16: 41–49.
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The Journal of Headache and Pain. 2018; 19: 13.
Kennis K, Kernick D, O’Flynn N. Diagnosis and management of headaches in young people and adults: NICE guideline. British Journal of General Practice. 2013; 63: 443–445.
Zheng H, Huang S, Chen Y, Tang T, Qin D, Chen M. Topiramate, acupuncture, and BoNT‐A for chronic migraine: a network meta‐analysis. Acta Neurologica Scandinavica. 2021; 143: 558–568.
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019; 9: e027953.
Lipton RB, Silberstein SD. Episodic and Chronic Migraine Headache: Breaking down Barriers to Optimal Treatment and Prevention. Headache. 2015; 55: 103–122.
Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019; 11: 459.
Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: a review of the mode of action in migraine. Acta Neurologica Scandinavica. 2018; 137: 442–451.
Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: mechanisms of action. British Journal of Pharmacology. 2014; 171: 4177–4192.
Choi YJ, Lee WJ, Lee HJ, Lee KW, Kim HJ, Hu KS. Effective Botulinum Toxin Injection Guide for Treatment of Temporal Headache. Toxins (Basel). 2016; 8: 265.
Kim YG, Bae JH, Kim H, Wang SJ, Kim ST. A Proposal for Botulinum Toxin Type A Injection Into the Temporal Region in Chronic Migraine Headache. Toxins (Basel). 2020; 12: 214.
Talbet JH, Elnahry AG. OnabotulinumtoxinA for the treatment of headache: an updated review. Journal of Integrative Neuroscience. 2022; 21: 037.
Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, et al. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Review of Neurotherapeutics. 2020; 20: 1275–1286.
Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine. Headache. 2012; 52: 409–421.
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56: S20–S28.
Cole JC, Lin P, Rupnow MF. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version. Cephalalgia. 2009; 29: 1180–1187.
Fischer D. Capturing the Patient’s View of Change as a Clinical Outcome Measure. The Journal of the American Medical Association. 1999; 282: 1157.
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021; 61: 1021–1039.
Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. The Journal of Headache and Pain. 2015; 17: 1.
Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N, Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015; 35: 864–868.
Packard A, Arciniegas AA, Smotherman C. Effectiveness of preventive onabotulinumtoxin a injections for migraine headaches is dependent on the circadian time of administration. Chronobiology International. 2021; 38: 576–583.
Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatric Disease and Treatment. 2013; 9: 709–720.
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019; 394: 1030–1040.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. New England Journal of Medicine. 2017; 377: 2113–2122.
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020; 94: e1365–e1377.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018; 91: e2211–e2221.
Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. The Journal of Headache and Pain. 2020; 21: 32.
Zhu S, Marmura MJ. Non-Invasive Neuromodulation for Headache Disorders. Current Neurology and Neuroscience Reports. 2016; 16: 11.
Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010; 50: 1153–1163.
Hong P, Liu Y, Wan Y, Xiong H, Xu Y. Transcranial direct current stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. CNS Neuroscience & Therapeutics. 2022; 28: 992–998.
Schwedt TJ. Chronic migraine. British Medical Journal. 2014; 348: g1416.
Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: a Retrospective Chart Review. Pain and Therapy. 2021; 10: 809–826.
Pimenta LDS, de Araújo ELM, Silva JPDS, França JJ, Brito PNA, de Holanda LJ, et al. Effects of Synergism of Mindfulness Practice Associated with Transcranial Direct-Current Stimulation in Chronic Migraine: Pilot, Randomized, Controlled, Double-Blind Clinical Trial. Frontiers in Human Neuroscience. 2021; 15: 769619.
Noseda R, Burstein R. Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013; 154: S44–S53.
Diener HC, Dodick DW, Turkel CC, Demos G, DeGryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. European Journal of Neurology. 2014; 21: 851–859.
Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, et al. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Headache. 2019; 59: 1700–1713.
Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (Botox) and topiramate (Topamax) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009; 49: 1466–1478.
Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. The Journal of Headache and Pain. 2019; 20: 26.
Tinsley A, Rothrock JF. Safety and tolerability of preventive treatment options for chronic migraine. Expert Opinion on Drug Safety. 2021; 20: 1523–1533.
Botox [package insert]. Allergan Ltd. plc: Dublin, Ireland. 2017.
OnabotulinumtoxinA. Drugs and lactation database (LactMed). National Library of Medicine (US): Bethesda (MD). 2020.
Brin MF, Kirby RS, Slavotinek A, Miller-Messana MA, Parker L, Yushmanova I, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA update: 29 years of safety observation. Headache. 2020; 60: 1–156.
Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, et al. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. Journal of Neural Transmission. 2016; 123: 533–540.
Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. The Journal of Headache and Pain. 2017; 18: 93.
Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache Impact of Chronic and Episodic Migraine: Results from the American Migraine Prevalence and Prevention Study. Headache. 2012; 52: 3–17.
Blumenfeld A, Varon S, Wilcox T, Buse D, Kawata A, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011; 31: 301–315.
Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011; 31: 837–850.
Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, et al. Life with Migraine: Effects on Relationships, Career, and Finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2019; 59: 1286–1299.
Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, et al. Impact of Migraine on the Family: Perspectives of People with Migraine and their Spouse/Domestic Partner in the CaMEO Study. Mayo Clinic Proceedings. 2016; 91: 596–611.
Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015; 35: 563–578.
Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). The Journal of Headache and Pain. 2012; 13: 361–378.
Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, et al. Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and Therapy. 2021; 10: 637–650.
Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B, et al. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. Journal of Medical Economics. 2020; 23: 113–123.
Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The Journal of Headache and Pain. 2021; 22: 50.
Rothrock JFSR, Sommer K, Blumenfeld AM. Healthcare resource utilization in adult patients treated with Onabotulinumtoxina for Chronic Migraine: results from the COMPEL study. Headache. 2019; 59: 108.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Back to top